<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> may be a risk factor for <z:e sem="disease" ids="C0011881" disease_type="Disease or Syndrome" abbrv="">diabetic kidney disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We examined prospectively association between the use of <z:chebi fb="0" ids="35664">statins</z:chebi> and development of <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A consecutive cohort of 5264 diabetic patient recruited between 1996 and 2005 underwent detailed assessments </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000082'>Renal dysfunction</z:hpo> was defined as first estimated glomerular filtration rate &lt;60 ml/min/1.73 m(2), or, the first hospitalisation with a diagnosis of <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> as coded by the International Classification of Disease, Ninth Revision </plain></SENT>
<SENT sid="4" pm="."><plain>Drug use was quantified using the proportion of exposure time from baseline to event/<z:hpo ids='HP_0011420'>death</z:hpo>/censored time, as appropriate </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In this cohort (male: 47.3%, median age: 55 years, median duration of <z:mp ids='MP_0002055'>diabetes</z:mp>: 6.0 years), none had <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> at baseline </plain></SENT>
<SENT sid="6" pm="."><plain>During a median follow-up period of 4.9 (quartiles: 2.77, 7.04) years, 703 patients (13.4%) developed <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo>, 1275 patients (22.2%) were exposed to <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>After controlling for baseline risk factors, multivariable adjusted hazard ratio of <z:chebi fb="0" ids="35664">statin</z:chebi> use for development of <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> was 0.32 (95% CI 0.21-0.50, p&lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Use of <z:chebi fb="0" ids="35664">statins</z:chebi> was associated with reduced risk of developing <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and this association was independent of baseline risk factors </plain></SENT>
</text></document>